Trial Outcomes & Findings for Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome (NCT NCT01190891)

NCT ID: NCT01190891

Last Updated: 2016-04-29

Results Overview

The SPADI is a 100-point, 13 item self-administered questionnaire divided into two subscales (pain and disability), with higher scores indicating greater pain and disability. It is responsive to change and accurately discriminates between patients who are improving or worsening. It has high test-retest reliability and internal consistency. The minimal detectable change (MDC) is 18 and the minimally clinically important difference (MCID) is between 8-13 points. The validity and responsiveness to change of SPADI have been described in physical therapy, as well as primary and secondary care settings.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

104 participants

Primary outcome timeframe

1 year

Results posted on

2016-04-29

Participant Flow

Participant milestones

Participant milestones
Measure
Manual Physical Therapy
The orthopaedic manual physical therapy (OMPT) intervention approach used in this study was based on an impairment model. The physical therapist providing the intervention addressed impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients received procedures tailored to their specific impairments. Procedures included mobilizations and manipulations of the joint and soft-tissues. Manual Physical Therapy: Same as arm description
Corticosteroid Injection (Subacromial)
Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL Corticosteroid Injection: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Overall Study
STARTED
52
52
Overall Study
COMPLETED
46
52
Overall Study
NOT COMPLETED
6
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Manual Physical Therapy
The orthopaedic manual physical therapy (OMPT) intervention approach used in this study was based on an impairment model. The physical therapist providing the intervention addressed impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients received procedures tailored to their specific impairments. Procedures included mobilizations and manipulations of the joint and soft-tissues. Manual Physical Therapy: Same as arm description
Corticosteroid Injection (Subacromial)
Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL Corticosteroid Injection: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Overall Study
Protocol Violation
1
0
Overall Study
Withdrawal by Subject
5
0

Baseline Characteristics

Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Manual Physical Therapy
n=46 Participants
Manual Physical Therapy: Same as arm description
Corticosteroid Injection (Subacromial)
n=52 Participants
Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL Corticosteroid Injection: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Total
n=98 Participants
Total of all reporting groups
Age, Continuous
40 years
STANDARD_DEVIATION 12 • n=5 Participants
42 years
STANDARD_DEVIATION 12 • n=7 Participants
41 years
STANDARD_DEVIATION 12 • n=5 Participants
Sex: Female, Male
Female
17 Participants
n=5 Participants
14 Participants
n=7 Participants
31 Participants
n=5 Participants
Sex: Female, Male
Male
29 Participants
n=5 Participants
38 Participants
n=7 Participants
67 Participants
n=5 Participants
Region of Enrollment
United States
46 participants
n=5 Participants
52 participants
n=7 Participants
98 participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 year

The SPADI is a 100-point, 13 item self-administered questionnaire divided into two subscales (pain and disability), with higher scores indicating greater pain and disability. It is responsive to change and accurately discriminates between patients who are improving or worsening. It has high test-retest reliability and internal consistency. The minimal detectable change (MDC) is 18 and the minimally clinically important difference (MCID) is between 8-13 points. The validity and responsiveness to change of SPADI have been described in physical therapy, as well as primary and secondary care settings.

Outcome measures

Outcome measures
Measure
Manual Physical Therapy
n=46 Participants
The orthopaedic manual physical therapy (OMPT) intervention approach used in this study was based on an impairment model. The physical therapist providing the intervention addressed impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients received procedures tailored to their specific impairments. Procedures included mobilizations and manipulations of the joint and soft-tissues. Manual Physical Therapy: Same as arm description
Corticosteroid Injection (Subacromial)
n=52 Participants
Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL Corticosteroid Injection: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Shoulder Pain and Disability Index
21.6 units on a scale
Interval 16.0 to 27.2
23.1 units on a scale
Interval 17.7 to 28.6

SECONDARY outcome

Timeframe: 1 year

The GROC questionnaire is an instrument that measures overall changes in the quality of life of the subject. The use of a GROC is a common, feasible, and useful method for assessing outcome, and has been shown to be a valid measurement of change in patient status in other pain populations. A change in score of three rating points has been established as a clinically significant in the patients perception of quality of life. The GROC has 15 possible choices, with 0 being equal to no change and -1 to -7 indicating a negative change and +1 to +7 indicating a positive change.

Outcome measures

Outcome measures
Measure
Manual Physical Therapy
n=46 Participants
The orthopaedic manual physical therapy (OMPT) intervention approach used in this study was based on an impairment model. The physical therapist providing the intervention addressed impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients received procedures tailored to their specific impairments. Procedures included mobilizations and manipulations of the joint and soft-tissues. Manual Physical Therapy: Same as arm description
Corticosteroid Injection (Subacromial)
n=52 Participants
Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL Corticosteroid Injection: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Global Rating of Change
3 units on a scale
Interval 2.0 to 4.0
3 units on a scale
Interval 2.0 to 4.0

Adverse Events

Manual Physical Therapy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Corticosteroid Injection (Subacromial)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Troy Patience, Research Operations Service

Madigan Army Medical Center

Phone: (253) 968-1160

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place